Search
Peginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigationalSymptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.
Bosentan
go.drugbank.com/drugs/DB00559ApprovedInvestigationalBosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. … Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Bexarotene
go.drugbank.com/drugs/DB00307ApprovedInvestigationalBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Donidalorsen
go.drugbank.com/drugs/DB18751ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin. … [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]
Thrombin alfa
go.drugbank.com/drugs/DB11572ApprovedThrombin Alfa precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic … because the incidence of hemostasis within a timely manner is relatively comparable between the use of thrombin alfa and the placebo treatment in patient subjects, thrombin alfa is not currently approved by
Sotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors … [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative … [L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant]
Dichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269Approved[L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773] … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.
DL-Methylephedrine
go.drugbank.com/drugs/DB11278ApprovedMethylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836].
Desloratadine
go.drugbank.com/drugs/DB00967ApprovedInvestigationalDesloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a l...
Mixtures: Aerius D-12 Modified Release Tablets 2.5mg/120mg, AXIVOL PLUS 2.5 MG / 120MG EFERVESAN TABLET, 20 ADETProducts: CRISTHALER 50MG/100 ML, DESLORIX 50MG/100ML JARABE